Acute and persistent nociceptive paw sensitisation in mice: the involvement of distinct signalling pathways.
OBJECTIVE
Many fundamental pharmacological studies in pain and inflammation have been performed on rats. However, the pharmacological findings were generally not extended to other species in order to increase their predictive therapeutic value. We studied acute and chronic inflammatory nociceptive sensitisation of mouse hind paws by prostaglandin E(2) (PGE(2)) or dopamine (DA), as previously described in rats. We also investigated the participation of the signalling pathways in acute and persistent sensitisation.


METHODS
Mechanical sensitisation (hypernociception) induced by intraplantar administrations of PGE(2) or DA was evaluated with an electronic pressure meter. The signalling pathways were pharmacologically investigated with the pre-administration of adenylyl cyclase (AC), cAMP-dependent protein kinase (PKA), protein kinase Cepsilon (PKCepsilon), and the extracellular signal-related kinase (ERK) inhibitors.


RESULTS
Single or 14days of successive intraplantar injections of PGE(2) or DA-induced acute and persistent hypernociception (lasting for more than 30days), respectively. The involvement of AC, PKA or PKCepsilon was observed in the acute hypernociception induced by PGE(2), while PKA or PKCepsilon were continuously activated during the period of persistent hypernociception. The acute hypernociception induced by DA involves activation of ERK, PKCepsilon, AC or PKA, while persistent hypernociception implicated ERK activation, but not PKA, PKCepsilon or AC.


CONCLUSIONS
In mice, acute and persistent paw sensitisation involves the different activation of kinases, as previously described for rats. This study opens the possibility of comparing pharmacological approaches in both species to further understand acute and chronic inflammatory sensitisation, and possibly associated genetic manipulations.
Villarreal
Cristiane F
CF
Faculty of Pharmacy, Federal University of Bahia, Bahia, Brazil.
Funez
Mani I
MI
Figueiredo
Florêncio
F
Cunha
Fernando Q
FQ
Parada
Carlos A
CA
Ferreira
Sérgio H
SH
D000818:Animals; D015232:Dinoprostone / Q000494:pharmacology*; D004298:Dopamine / Q000494:pharmacology*; D006614:Hindlimb / Q000187:drug effects* / Q000276:immunology; D007249:Inflammation; D008297:Male; D051379:Mice; D010120:Oxytocics / Q000494:pharmacology*; D010147:Pain Measurement; D010770:Phosphotransferases / Q000378:metabolism; D015398:Signal Transduction; D013566:Sympathomimetics / Q000494:pharmacology*
D010120:Oxytocics; D013566:Sympathomimetics; D010770:Phosphotransferases; D015232:Dinoprostone; D004298:Dopamine